Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITI Jr: Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT04673357Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of ustekinumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Apr 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04673357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673357.